Pharma BD Deal Intelligence
Roche acquired Telavant Holdings from Roivant Sciences in a deal announced October 23, 2023 and completed December 14, 2023, paying $7.1 billion upfront plus a $150 million near-term milestone (up to $7.25 billion). The transaction gave Roche US and Japanese development, manufacturing and commercialization rights to RVT-3101, a novel anti-TL1A (TNFSF15) IgG1 monoclonal antibody for inflammatory bowel disease; Pfizer retained rights outside those territories and Roche also took an option on a next-generation p40/TL1A bispecific. The asset was Phase 3-ready on Phase 2b TUSCANY-2 data showing 36% clinical remission and 50% endoscopic improvement at week 56 in ulcerative colitis. Under Roche the antibody was renamed afimkibart (RG6631 / RO7790121) and advanced to Phase III in ulcerative colitis (Ametrine-2, NCT06588855, initiated December 2024) and Phase II in Crohn's disease and atopic dermatitis, with Roche guiding to a first regulatory filing in UC around 2027.